Genedrive PLC
LSE:GDR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.45
9.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genedrive PLC
Cash & Cash Equivalents
Genedrive PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genedrive PLC
LSE:GDR
|
Cash & Cash Equivalents
£1.2m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-13%
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cash & Cash Equivalents
£220.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cash & Cash Equivalents
£16.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Cash & Cash Equivalents
£26m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
Cash & Cash Equivalents
£13.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Cash & Cash Equivalents
£37.1m
|
CAGR 3-Years
36%
|
CAGR 5-Years
52%
|
CAGR 10-Years
65%
|
|
Genedrive PLC
Glance View
Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.
See Also
What is Genedrive PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.2m
GBP
Based on the financial report for Dec 31, 2023, Genedrive PLC's Cash & Cash Equivalents amounts to 1.2m GBP.
What is Genedrive PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-13%
Over the last year, the Cash & Cash Equivalents growth was -41%. The average annual Cash & Cash Equivalents growth rates for Genedrive PLC have been -31% over the past three years , -27% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet
